Anixa Biosciences, Inc. (ANIX)

NASDAQ: ANIX · IEX Real-Time Price · USD
3.480
+0.040 (1.16%)
Feb 27, 2024, 12:01 PM EST - Market open
1.16%
Market Cap 109.09M
Revenue (ttm) 210,000
Net Income (ttm) -9.81M
Shares Out 31.71M
EPS (ttm) -0.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 32,251
Open 3.490
Previous Close 3.440
Day's Range 3.460 - 3.562
52-Week Range 2.750 - 6.450
Beta 0.92
Analysts Strong Buy
Price Target 10.50 (+201.72%)
Earnings Date Mar 15, 2024

About ANIX

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also develop... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 1, 1987
Employees 4
Stock Exchange NASDAQ
Ticker Symbol ANIX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for ANIX stock is "Strong Buy." The 12-month stock price forecast is $10.5, which is an increase of 201.72% from the latest price.

Price Target
$10.5
(201.72% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial

Dose escalation for fourth patient follows successful completion of first cohort SAN JOSE, Calif. , Feb. 12, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a c...

15 days ago - PRNewsWire

Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference

Conference Investment Track spotlights promising and emerging biotech and healthcare companies advancing the field of oncology SAN JOSE, Calif. , Jan. 29, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ...

4 weeks ago - PRNewsWire

Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology

Broad coverage extended to Japan and related regions SAN JOSE, Calif., Jan. 23, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology c...

5 weeks ago - PRNewsWire

Anixa Biosciences to Present at Sidoti Micro-Cap Virtual Conference on January 17, 2024

SAN JOSE, Calif. , Jan. 10, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of ca...

6 weeks ago - PRNewsWire

Anixa Biosciences to Present at Biotech Showcase 2024

SAN JOSE, Calif. , Dec. 14, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of ca...

2 months ago - PRNewsWire

Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine

– Antigen-specific T cell responses were observed at all dose levels – – IFNγ and IL-17, immune-mediated biomarkers of T cell activation, increased over time from baseline – – Vaccine was safe and wel...

2 months ago - PRNewsWire

Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine

– Data to be released at approximately 6:00 p.m. ET, following presentation at 2023 SABCS – – Conference call to commence at 6:30 p.m.

2 months ago - PRNewsWire

Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology

SAN JOSE, Calif. , Nov. 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann...

3 months ago - PRNewsWire

Anixa Biosciences to Present at the Ovarian Cancer Research Alliance (OCRA) Ovarian Cancer National Conference

Company to present on its ongoing Phase 1 ovarian cancer CAR-T trial SAN JOSE, Calif. , Oct. 31, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology...

4 months ago - PRNewsWire

Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board

SAN JOSE, Calif. , Oct. 23, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann...

4 months ago - PRNewsWire

Anixa Biosciences Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial

- With no dose-limiting toxicities observed, treatment of second dose cohort to begin SAN JOSE, Calif. , Oct. 13, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX)...

4 months ago - PRNewsWire

Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology

SAN JOSE, Calif. , Oct. 3, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today anno...

5 months ago - PRNewsWire

Anixa Biosciences Establishes Cancer Business Advisory Board

SAN JOSE, Calif. , Sept. 19, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today an...

5 months ago - PRNewsWire

Anixa Biosciences to Participate in September Investor Conferences

SAN JOSE, Calif. , Aug. 31, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann...

6 months ago - PRNewsWire

Anixa Biosciences Announces Treatment of Third Patient in Ovarian Cancer CAR-T Clinical Trial

SAN JOSE, Calif. , Aug. 28, 2023 /PRNewswire/ --  Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today an...

6 months ago - PRNewsWire

Anixa Biosciences Announces Invited Presentation on Ovarian Cancer CAR-T Therapy at the 8th Annual CAR-TCR Summit

SAN JOSE, Calif. , Aug. 14, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann...

7 months ago - PRNewsWire

Could Anixa Biosciences (NASDAQ:ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer?

SAN JOSE, CA / ACCESSWIRE / August 10, 2023 / Cancer is a disease that affects millions of people around the world. Historically, cancer vaccines have not been very successful in treating or preventin...

7 months ago - Accesswire

Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial

SAN JOSE, Calif. , Aug. 7, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today anno...

Other symbols: MRK
7 months ago - PRNewsWire

Anixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian Cancer Vaccine Technology

SAN JOSE, Calif. , July 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann...

7 months ago - PRNewsWire

Anixa Biosciences Announces Issuance of Canadian Patent for its CAR-T Cancer Therapy Technology

— Technology currently being evaluated for the treatment of ovarian cancer in Phase 1 clinical trial — SAN JOSE, Calif. , July 11, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company...

8 months ago - PRNewsWire

Anixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer CAR-T Clinical Trial

SAN JOSE, Calif. , May 22, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that, in conjunction ...

10 months ago - PRNewsWire

Anixa Biosciences Clarifies Poster Presentation on Company Website

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that a technical error was made by the company's website hosting servi...

11 months ago - PRNewsWire

Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine

SAN JOSE, Calif., April 17, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that Cleveland Clinic...

11 months ago - PRNewsWire

Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2023 AACR Annual Meeting

SAN JOSE, Calif. , March 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation on r...

1 year ago - PRNewsWire

Anixa Biosciences Reassures Shareholders It Has No Accounts at Silicon Valley Bank

SAN JOSE, Calif. , March 13, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today reassured its shareholders an...

1 year ago - PRNewsWire